What is the pathophysiology of multiple sclerosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 24, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pathophysiology of Multiple Sclerosis

Multiple sclerosis results from unfavorable interactions between genetic susceptibility and environmental factors—particularly Epstein-Barr virus—that trigger activation and migration of pro-inflammatory B cells and T cells into the CNS, leading to focal demyelination, axonal injury, and progressive neurodegeneration that begins early in the disease course. 1

Core Pathological Mechanisms

MS involves two interconnected pathological processes that occur simultaneously 1:

  • Inflammatory component: Autoimmune-mediated demyelination driven by myelin-specific CD4+ and CD8+ T cells that attack the myelin sheath 1
  • Neurodegenerative component: Irreversible demyelination, axonal transection, and neuronal loss that causes permanent disability 1

The disease is characterized by widespread focal degradation of the myelin sheath with variable axonal and neuronal injury 2

Immunological Mechanisms

T Cell-Mediated Pathology

The primary drivers of CNS damage are specific T helper cell populations 3, 4:

  • Th1 cells produce interferon-γ and are essential for differentiation of encephalitogenic CD8+ T cells 3
  • Th17 cells produce interleukin-17 and cross the blood-brain barrier to directly target myelin in the CNS 3, 5
  • Th17.1 cells share hallmarks of both Th1 and Th17 subsets and play a pivotal role in disease pathogenesis 5
  • CD8+ T lymphocytes participate in the development of MS lesions and are found abundantly in CNS tissue 6

These autoreactive lymphocytes are found in high levels in CNS lesions and cerebrospinal fluid of MS patients, contributing to blood-brain barrier breakdown and activation of resident astrocytes and microglia 4

B Cell Contributions

B cells contribute through multiple mechanisms 1:

  • Antibody production, including anti-myelin basic protein antibodies 3
  • Antigen presentation to T cells 1
  • Production of pro-inflammatory cytokines that amplify the immune response 3

Regulatory Cell Dysfunction

Aberrant function of regulatory T cells (Tregs) and Th9 cells contributes to loss of immune tolerance and perpetuation of inflammation 3

Environmental Triggers and Risk Factors

Epstein-Barr virus is recognized as the key environmental trigger that leads to immune dysregulation in genetically susceptible individuals 1, 2

Additional environmental factors include 2:

  • Vitamin D deficiency and low sunlight exposure are associated with increased MS risk 1, 2
  • Dietary factors, with diets lower in saturated fat and higher in polyunsaturated fatty acids potentially protective 2
  • Geographic variability, with higher incidence in regions with lower sunlight exposure 2

Pathological Lesion Types

Subpial Demyelination

Subpial demyelination is associated with meningeal inflammation and intrathecal pro-inflammatory profiles, and appears highly specific for MS based on pathology studies, though it goes largely undetected even with advanced MRI techniques 7

Chronic Active Lesions

Up to 57% of chronic MS lesions are active or mixed (active and inactive), characterized by ongoing inflammatory activity at lesion edges despite appearing chronic on conventional imaging 7

Clinical Course

The disease manifests in two main forms 2:

  • Relapsing-remitting MS (RRMS): Affects approximately 85% of cases with discrete attacks followed by recovery periods 2
  • Primary-progressive MS (PPMS): Affects approximately 15% of cases with gradual worsening from onset 2

MS is a continuous, progressive, lifelong disease with a variable course that includes a long latent period from initial infection to symptom onset, followed by progressive acceleration 2

Critical Pathophysiological Pitfall

Current disease-modifying therapies primarily target the inflammatory component rather than promoting remyelination or neuroprotection, which explains why they reduce relapse rates by 29-68% but do not reverse existing damage 1, 8. The neurodegenerative component begins early in the disease course and continues even when inflammation is controlled, emphasizing the importance of early aggressive treatment 1

References

Guideline

Pathophysiology and Treatment of Multiple Sclerosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Multiple Sclerosis Pathogenesis and Risk Factors

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Multiple Sclerosis and T Lymphocytes: An Entangled Story.

Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2015

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Teriflunomide's Mechanism and Effects in Multiple Sclerosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.